60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.61) per share and revenue of $0.27 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.
60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16). The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, analysts expect 60 Degrees Pharmaceuticals to post ($3.31) EPS for the current fiscal year and ($2.14) EPS for the next fiscal year.
60 Degrees Pharmaceuticals Trading Down 8.2%
NASDAQ:SXTP opened at $0.55 on Tuesday. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.52 and a fifty-two week high of $8.62. The stock has a fifty day moving average price of $0.98 and a 200-day moving average price of $1.74.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.85.
Read Our Latest Analysis on 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent.
Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.
Further Reading
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
